The fagerström test for nicotine dependence as a predictor of smoking abstinence: A pooled analysis of varenicline clinical trial data

Nicotine and Tobacco Research

Volumn 14, Issue 12, 2012, Pages 1467-1473

  Fagerström, Karl ^a   Russ, Cristina ^b   Yu, Ching Ray ^b   Yunis, Carla ^b   Foulds, Jonathan ^c  

^a Smoker's Information Centre   (Sweden)

^b PFIZER INC   (United States)

^c PENNSYLVANIA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; VARENICLINE;

ADULT; ARTICLE; CLINICAL ASSESSMENT TOOL; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FAGERSTROM TEST FOR NICOTINE DEPENDENCE; FEMALE; HEAVINESS OF SMOKING INDEX; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCORING SYSTEM; SMOKING CESSATION; TOBACCO DEPENDENCE;

ADULT; BENZAZEPINES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; NICOTINIC AGONISTS; PLACEBO EFFECT; QUESTIONNAIRES; QUINOXALINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SMOKING; SMOKING CESSATION; TOBACCO USE DISORDER;

EID: 84870403521     PISSN: 14622203     EISSN: 1469994X     Source Type: Journal    
DOI: 10.1093/ntr/nts018     Document Type: Article

References (34)

1. Aubin, H. J., Bobak, A., Britton, J. R., Oncken, C., Billing, C. B., Jr ., Gong, J., et al. (2008). Varenicline versus transdermal nicotine patch for smoking cessation: Results from a randomised openlabel trial. Thorax, 63, 717-724. doi:10.1136/thx.2007.090647
2. Baker, T. B., Breslau, N., Covey, L., & Shiffman, S. (2012). DSM criteria for tobacco use disorder and tobacco withdrawal: A critique and proposed Revisions for DSM-5. Addiction, 107, 263-275. doi:10.1111/j.1360-0443.2011.03657
3. Baker, T. B., Piper, M. E., McCarthy, D. E., Bolt, D. M., Smith, S. S., Kim, S. Y., et al. (2007). Time to first cigarette in the morning as an index of ability to quit smoking: Implications for nicotine dependence. Nicotine & Tobacco Research, 9 (Suppl. 4), S555-S570. doi:10.1080/14622200701673480
4. Bolliger, C. T., Issa, J. S., Posadas-Valay, R., Safwat, T., Abreu, P., Correia, E. A., et al. (2011). Effects of varenicline in adult smokers: A multinational, 24-week, randomized, double-blind, placebo-controlled study. Clinical Therapeutics, 33, 465-477. doi:S0149-2918(11)00196-2 [pii]10.1016/j.clinthera.2011.04.013
5. Breslau, N., & Johnson, E. O. (2000). Predicting smoking cessation and major depression in nicotine-dependent smokers. American Journal of Public Health, 90, 1122-1127. doi:10.2105/AJPH.90.7.1122
6. Fagerström, K. (2012). Commentary on Baker et al: DSM criteria for tobacco use disorder and tobacco withdrawal: A critique and proposed revisions for DSM-5. Addiction, 107, 276-277. doi:10. 1111/j.1360-0443.2011.03657.x
7. Fagerström, K., & Furberg, H. (2008). A comparison of the Fagerström Test for Nicotine Dependence and smoking prevalence across countries. Addiction, 103, 841-845. doi:10.1111/j.1360-0443.2008.02190.x
8. Fagerström, K., Gilljam, H., Metcalfe, M., Tonstad, S., & Messig, M. (2010). Stopping smokeless tobacco with varenicline: Randomised double blind placebo controlled trial. British Medical Journal, 341, c6549. doi:10.1136/bmj.c6549
9. Fidler, J. A., Shahab, L., & West, R. (2011). Strength of urges to smoke as a measure of severity of cigarette dependence: Comparison with the Fagerström Test for Nicotine Dependence and its components. Addiction, 106, 631-638. doi:10.1111/j.1360-0443.2010.03226.x
10. Fiore, M. C., Jaén, C. R., Baker, T.B., Bailey, W. C., Benowitz, N. L.
11. Curry, S. J., et al. (2008). Clinical practice guideline. Treating tobacco use and dependence: 2008 Update. Retrieved from http://www.surgeongeneral.gov/tobacco/treating_tobacco_use08.pdf
12. Garza, D., Murphy, M., Tseng, L. J., Riordan, H. J., & Chatterjee, A. (2011). A double-blind randomized placebocontrolled pilot study of neuropsychiatric adverse events in abstinent smokers treated with varenicline or placebo. Biological Psychiatry, 69, 1075-1082. doi:10.1016/j.biopsych.2010.12.005
13. GlaxoSmithKline. (2012). Nicorette U.S. product information. Retrieved from http://www.nicorette.com/quit-smoking-products/nicorette-gum.aspx
14. Gonzales, D., Rennard, S. I., Nides, M., Oncken, C., Azoulay, S., Billing, C. B., et al. (2006). Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: A randomized controlled trial. Journal of the American Medical Association, 296, 47-55. doi:10.1001/jama.296.1.47
15. Heatherton, T. F., Kozlowski, L. T., Frecker, R. C., & Fagerström, K. O. (1991). The Fagerström Test for Nicotine Dependence: A revision of the Fagerström Tolerance Questionnaire. British Journal of Addiction, 86, 1119-1127. doi:10.1111/j.1360-0443.1991.tb01879.x
16. Jorenby, D. E., Hays, J. T., Rigotti, N. A., Azoulay, S., Watsky, E. J., Williams, K. E., et al. (2006). Efficacy of varenicline, an alpha-4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: A randomized controlled trial. Journal of the American Medical Association, 296, 56-63.
17. Nakamura, M., Oshima, A., Fujimoto, Y., Maruyama, N., Ishibashi, T., & Reeves, K. R. (2007). Efficacy and tolerability of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers. Clinical Therapeutics, 29, 1040-1056. doi:10.1016/j.clinthera.2007.06.012
18. Niaura, R., Hays, J. T., Jorenby, D. E., Leone, F. T., Pappas, J. E., Reeves, K. R., et al. (2008). The efficacy and safety of varenicline for smoking cessation using a flexible dosing strategy in adult smokers: A randomized controlled trial. Current Medical Research and Opinion, 24, 1931-1941. doi:10.1185/030079908 02177523
19. Nides, M., Oncken, C., Gonzales, D., Rennard, S., Watsky, E. J., Anziano, R., et al. (2006). Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: Results from a 7-week, randomized, placebo- and bupropioncontrolled trial with 1-year follow-up. Archives of Internal Medicine, 166, 1561-1568. doi:10.1001/archinte.166.15.1561
20. Oncken, C., Gonzales, D., Nides, M., Rennard, S., Watsky, E., Billing, C. B., et al. (2006). Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Archives of Internal Medicine, 166, 1571-1577. doi:10.1001/archinte.166.15.1571
21. Pfizer Inc. (2007). Protocol No. A3051043: A multicenter, open-label study exploring the efficacy and safety of varenicline in Japanese smokers motivated to quit smoking. Retrieved from http://www.clinicalstudyresults.org/drugdetails/?study_name=A3051043&sort=c.company_name&page=1&drug_id=2602
22. Rennard, S. (2010). Randomized, placebo-controlled trial of varenicline for smoking cessation with flexible quit dates. Presented at the 20th Annual Congress of the European Respiratory Society, September 18-22, 2010; Barcelona, Spain. Retrieved from www. erscongress2010.org/
23. Rigotti, N. A., Pipe, A. L., Benowitz, N. L., Arteaga, C., Garza, D., & Tonstad, S. (2010). Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease:A randomized trial. Circulation, 121, 221-229. doi:10.1161/CIRCULATIONAHA.109.869008
24. Stapleton, J. A., & Sutherland, G. (2011). Treating heavy smokers in primary care with the nicotine nasal spray: Randomized placebo-controlled trial. Addiction, 106, 824-832. doi:10.1111/j.1360-0443.2010.03274.x
25. Sutherland, G., Stapleton, J. A., Russell, M. A., Jarvis, M. J., Hajek, P., Belcher, M., et al. (1992). Randomised controlled trial of nasal nicotine spray in smoking cessation. The Lancet, 340, 324-329. doi:10.1016/0140-6736(92)91403-U
26. Tashkin, D. P., Rennard, S., Hays, J. T., Ma, W., Lawrence, D., & Lee, T. C. (2011). Effects of varenicline on smoking cessation in patients with mild to moderate COPD: A randomized controlled trial. Chest, 139, 591-599. doi:10.1378/chest.10-0865
27. The Royal College of Physicians. (2000). Nicotine addiction in Britain. A report of the tobacco advisory group of the Royal College of Physicians. Retrieved from http://bookshop.rcplondon.ac.uk/contents/pub131-2740272e-57b4-4567-b87c-cda5ef7cd7e0.pdf
28. Tønnesen, P., Fryd, V., Hansen, M., Helsted, J., Gunnersen, A. B., Forchammer, H., et al. (1988). Effect of nicotine chewing gum in combination with group counseling on the cessation of smoking. New England Journal of Medicine, 318, 15-18. doi:10.1056/NEJM 198801073180104
29. Tonstad, S., Tonnesen, P., Hajek, P., Williams, K. E., Billing, C. B., & Reeves, K. R. (2006). Effect of maintenance therapy with varenicline on smoking cessation: A randomized controlled trial. Journal of the American Medical Association, 296, 64-71. doi:10.1001/jama.296.1.64
30. Tsai, S. T., Cho, H. J., Cheng, H. S., Kim, C. H., Hsueh, K. C., Billing, C. B., Jr ., et al. (2007). A randomized, placebocontrolled trial of varenicline, a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers. Clinical Therapeutics, 29, 1027-1039. doi:10.1016/j.clinthera.2007.06.011
31. U.S. Department of Health and Human Services. (2010). H ow tobacco smoke causes disease: The biology and behavioral basis for smoking-attributable disease: A report of the Surgeon General.
32. U.S. Department of Health and Human Services, Public Health Service, Office of Surgeon General. Retrieved from www. ncbi. nlm. nih. gov
33. Wang, C., Xiao, D., Chan, K. P., Pothirat, C., Garza, D., & Davies, S. (2009). Varenicline for smoking cessation: A placebocontrolled, randomized study. Respirology, 14, 384-392. doi:10.1111/j.1440-1843.2008.01476.x
34. Williams, K. E., Reeves, K. R., Billing, C. B., Jr., Pennington, A. M., & Gong, J. (2007). A double-blind study evaluating the long-term safety of varenicline for smoking cessation. Current Medical Research and Opinion, 23, 793-801. doi:10.1185/030079 907X182185